Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 7Unknown 2Active not recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Ovarian Neoplasms 1Neoplasms 1

Interventions

Paclitaxel 9Carboplatin 8Bevacizumab 8fluzoparib 5olaparib 3Topotecan 3Gemcitabine 3liposomal doxorubicin 2famitinib 2apatinib 2Oxaliplatin 2Magnetic Resonance Spectroscopy 2Indocyanine Green 2Drug Therapy 2Cisplatin 2trametinib 1senaparib 1pembrolizumab 1niraparib 1montelukast 1irinotecan sucrosofate 1fludarabine 1durvalumab 1dalpiciclib 1dabrafenib 1ceralasertib 1anlotinib 1aldesleukin 1Ultrasonography, Doppler 1Therapeutics 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Ovarian Neoplasms × CP protocol × Clear all
NCT07401654 2026-02-10

The Efficacy and Safety of Paclitaxel Monotherapy Versus Paclitaxel-Carboplatin Combination as Neoadjuvant Chemotherapy in Advanced Ovarian Cancer With High PARK2 Expression

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase 2 Not yet recruiting
60 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡